Biogen Inc (NASDAQ:BIIB) soared 0.18% during previous trade, a total of 1.13M shares exchanged hands compared with its average trading volume of 1.60M shares whereas its relative volume is 0.69. The stock has a market capitalization of $59.05B along with 215.95M outstanding shares. Stock’s intraday price range hit the peak level of $274.90 and touched the lowest level of $271.62.
Most recently Biogen Inc (NASDAQ:BIIB)’s price target was revised on 04/20/17 and according to 24 analysts stock’s price will reach at $313.90 during 52 weeks with standard deviation of 35.23. Stock’s minimum price target estimates has been figured out at $260 while the maximum price target forecast is established at $380, if we look at the price target with an optimistic approach it has upside potential of 32% from its latest closing price of $272.94.
Historically, if we look at price target revisions, two weeks ago Biogen Inc (NASDAQ:BIIB)’s price target was revised on 04/06/17 by the analysts, however the bullish price estimates of the stock set at $380 while the bearish estimates kept at $265 over the next one year. Stock’s 52-week target was retained at $317.93, the estimates indicates a standard deviation of 34.76.
While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.75. ABR value is precisely based on brokerage recommendations, where out of 16 brokerage recommendations 10 rate Biogen Inc (NASDAQ:BIIB) stock a Strong Buy, 0 rate the stocks of the company a Buy, 6 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 3/16/17 the stock of Biogen Inc (NASDAQ:BIIB) downgraded by Leerink Partners from Outperform to Mkt Perform. However previously on 3/16/17 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 2/7/17 the stock was upgraded by Citigroup from Neutral to Buy.
Biogen Inc (NASDAQ:BIIB) performance over the past one year plunged -2.38% whereas its year to date (YTD) performance indicated a bearish trend of -3.75%. During the last six months the stock slipped -7.52%. Quarterly performance of the company shows declining momentum of -2.75% while its last one month trend is negative with -1.77%. Stock’s weekly performance expressed up trend of 0.39%.
The company’s price sits -2.68% below from its 50-day moving average of $277.55 and -6.20% below from the stock’s 200-day moving average which is $287.45. Biogen Inc (NASDAQ:BIIB)’s shares are currently trading -18.20% away from the 52-week high price of $333.65 and +22.38% far from the 52-week low price of $223.02.
According to consensus agreement of 22 analysts Biogen Inc (NASDAQ:BIIB) will report earnings per share of $5 in their quarterly report and it is expected to announce the company’s results on 4/25/17 /Before Market Open. For the current quarter the company has high EPS estimates of $5.28 in contradiction of low EPS estimates of $4.47. However a year ago for the same quarter the company has reported $4.79 EPS. Current year EPS projections for Biogen Inc (NASDAQ:BIIB) set at $20.96 according to the sentiments of 25 analysts, while its lowest earnings estimates are $20.01 and highest earnings estimates are $22.16.
According to 19 analysts, Biogen Inc (NASDAQ:BIIB)’s revenue estimates for the current quarter are $2.74B meanwhile the company has high revenue estimates of $2.82B in contradiction of low revenue estimates of $2.62B. For the current year the company’s revenue estimates are $11.27B compared to low analyst estimates of $10.81B and high estimates of $11.71B according to the projection of 23 analysts.